Please use this identifier to cite or link to this item:
|Title:||Molecular biomarkers in schizophrenia - implications for clinical practice|
|Authors:||Lee, J. |
|Source:||Lee, J., Chong, S.-A. (2010-05). Molecular biomarkers in schizophrenia - implications for clinical practice. Current Psychiatry Reviews 6 (2) : 114-121. ScholarBank@NUS Repository. https://doi.org/10.2174/157340010791196475|
|Abstract:||Schizophrenia is a serious mental illness and clinical diagnosis over the past century had been based on recognition of a certain pattern of thinking, perception and behavior. Although mostly people accept that the disease is a complex phenotypic presentation with a strong hereditary predisposition, the exact pathophysiology of schizophrenia has not been clearly elucidated. Rapid advancements in genomics, epigenomics, transcriptomics, proteomics and lipidomics had been made in the search for molecular biomarkers in schizophrenia which could potentially aid clinicians in understanding and subtyping psychosis. It could assist in diagnosis and selection of appropriate antipsychotic therapy, it also provides early indicators of clinical response. In this review, we discuss relevant literature with regards to these advancements, their challenges and their potential clinical impact. © 2010 Bentham Science Publishers Ltd.|
|Source Title:||Current Psychiatry Reviews|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Mar 10, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.